Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Antibody–drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-generation ADCs targeting HER2, such as [vic-]trastuzu...

Descripción completa

Detalles Bibliográficos
Autores principales: Duro-Sánchez, Santiago, Nadal-Serrano, Mercedes, Lalinde-Gutiérrez, Marta, Arenas, Enrique Javier, Bernadó Morales, Cristina, Morancho, Beatriz, Escorihuela, Marta, Pérez-Ramos, Sandra, Escrivá-de-Romaní, Santiago, Gandullo-Sánchez, Lucía, Pandiella, Atanasio, Esteve-Codina, Anna, Rodilla, Verónica, Dijcks, Fred A., Dokter, Wim H.A., Cortés, Javier, Saura, Cristina, Arribas, Joaquín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755966/
https://www.ncbi.nlm.nih.gov/pubmed/36222720
http://dx.doi.org/10.1158/0008-5472.CAN-22-0787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755966/
https://www.ncbi.nlm.nih.gov/pubmed/36222720
http://dx.doi.org/10.1158/0008-5472.CAN-22-0787

Ejemplares similares